Stumbles on the path to dengue control

The Lancet Infectious Diseases

Volumn 14, Issue 8, 2014, Pages 661-662

  Halstead, Scott B ^a  

^a NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CASTANOSPERMINE 6 BUTYRATE; PLACEBO;

ANTIVIRAL ACTIVITY; BLOOD VESSEL PERMEABILITY; DENGUE; DENGUE VIRUS; GEOGRAPHIC DISTRIBUTION; HEMOSTASIS; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION CONTROL; MAINTENANCE DRUG DOSE; NONHUMAN; NOTE; PHYSICAL DISEASE BY BODY FUNCTION; PRIORITY JOURNAL; UNSPECIFIED SIDE EFFECT; VECTOR CONTROL;

ANTIVIRAL AGENTS; DENGUE; FEMALE; HUMANS; INDOLIZINES; MALE;

EID: 84904750683     PISSN: 14733099     EISSN: 14744457     Source Type: Journal    
DOI: 10.1016/S1473-3099(14)70770-4     Document Type: Note

References (17)

1. Hammon WM, Rudnick A, Sather GE, Rogers KD, Morse LJ New hemorrhagic fevers of children in the Philippines and Thailand. Trans Assoc Am Physicians 1960, 73:140-155.
2. Brady OJ, Gething PW, Bhatt S, et al. Refining the global spatial limits of dengue virus transmission by evidence-based consensus. PLoS Negl Trop Dis 2012, 6:e1760.
3. Bhatt S, Gething PW, Brady OJ, et al. The global distribution and burden of dengue. Nature 2013, 496:504-507.
4. Halstead SB Dengue. Lancet 2007, 370:1644-1652.
5. Leo YS, Gan VC, Ng EL, et al. Utility of warning signs in guiding admission and predicting severe disease in adult dengue. BMC Infect Dis 2013, 13:498.
6. Gubler DJ Epidemic dengue/dengue hemorrhagic fever as a public health, social and economic problem in the 21st century. Trends Microbiol 2002, 10:100-103.
7. Sabchareon A, Wallace D, Sirivichayakul C, et al. Protective efficacy of the recombinant, live-attenuated, CYD tetravalent dengue vaccine in Thai schoolchildren: a randomised, controlled phase 2b trial. Lancet 2012, 380:1559-1567.
8. Low JG, Sung C, Wijaya L, et al. Efficacy and safety of celgosivir in patients with dengue fever (CELADEN): a phase 1b, randomised, double-blind, placebo-controlled, proof-of-concept trial. Lancet Infect Dis 2014, published online May 28. http://dx.doi.org/10.1016/S1473-3099(14)70730-3.
9. Tricou V, Minh NN, Van TP, et al. A randomized controlled trial of chloroquine for the treatment of dengue in Vietnamese adults. PLoS Negl Trop Dis 2010, 4:e785.
10. Nguyen NM, Tran CN, Phung LK, et al. A randomized, double-blind placebo controlled trial of balapiravir, a polymerase inhibitor, in adult dengue patients. J Infect Dis 2013, 207:1442-1450.
11. Courageot MP, Frenkiel MP, Dos Santos CD, Deubel V, Despres P Alpha-glucosidase inhibitors reduce dengue virus production by affecting the initial steps of virion morphogenesis in the endoplasmic reticulum. J Virol 2000, 74:564-572.
12. Rathore AP, Paradkar PN, Watanabe S, et al. Celgosivir treatment misfolds dengue virus NS1 protein, induces cellular pro-survival genes and protects against lethal challenge mouse model. Antiviral Res 2011, 92:453-460.
13. Schul W, Liu W, Xu HY, Flamand M, Vasudevan SG A dengue fever viremia model in mice shows reduction in viral replication and suppression of the inflammatory response after treatment with antiviral drugs. J Infect Dis 2007, 195:665-674.
14. Watanabe S, Rathore AP, Sung C, et al. Dose- and schedule-dependent protective efficacy of celgosivir in a lethal mouse model for dengue virus infection informs dosing regimen for a proof of concept clinical trial. Antiviral Res 2012, 96:32-35.
15. Muller DA, Young PR The flavivirus NS1 protein: molecular and structural biology, immunology, role in pathogenesis and application as a diagnostic biomarker. Antiviral Res 2013, 98:192-208.
16. Halstead SB Identifying protective dengue vaccines: guide to mastering an empirical process. Vaccine 2013, 31:4501-4507.
17. Tam DT, Ngoc TV, Tien NT, et al. Effects of short-course oral corticosteroid therapy in early dengue infection in Vietnamese patients: a randomized, placebo-controlled trial. Clin Infect Dis 2012, 55:1216-1224.